Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Treatment of Corticosteroid-Resistant Thyroid Eye Disease With Subcutaneous Tocilizumab
source: Canadian Journal of Ophthalmology
year: 2020
authors: Rona Z. Silkiss, Michael K. Paap, Kelsey A. Roelofs, Jorge Agi, Ezekiel Weis
summary/abstract:Within the last decade, novel biologics have emerged as a promising treatment for thyroid eye disease (TED), both as primary therapy and as an alternative to methotrexate or radiation in patients with steroid-refractory disease. Upregulation of several cytokines, including interleukin-6 (IL-6), have been implicated in the pathogenesis of TED. Tocilizumab (RoActemra, Hoffman-La Roche, Basel, Switzerland) is a recombinant humanized monoclonal antibody inhibitor of the IL-6 receptor. Its off-label intravenous use has been previously described in 2 case reports and a randomized trial to demonstrate clinical improvement in corticosteroid-resistant TED.
Although intravenous tocilizumab is well-tolerated in this patient population, intravenous administration is time-consuming and resource intensive, and an expensive off-label use of an U.S. Food and Drug Administration (FDA)-approved medication is generally not covered by insurance. Prior studies have demonstrated that the safety and efficacy of tocilizumab are unchanged when administered subcutaneously (SC) versus intravenously in patients with rheumatoid arthritis. In addition, a recent case series of 2 patients with TED demonstrated symptomatic improvement with 4 doses of 162 mg of tocilizumab delivered SC. To date, however, there have been no published reports that explore the immunological response of TED patients treated with SC tocilizumab, or whether the achieved suppression of disease activity lasts more than 6 months after the initiation of therapy.
organization: California Pacific Medical Center, USA; University of California, USA; Moorfields Eye Hospital, UK; University of Calgary, Canada; University of Alberta, CanadaDOI: 10.1016/j.jcjo.2020.07.020
read more
Related Content
-
TEPEZZA Has Resumed Production – FAQHorizon Therapeutics, the developer of T...
-
Immunotherapy for Graves’ OphthalmopathyPurpose of Review: In recent years, imm...
-
Early Experience With Teprotumumab for Chronic Thyroid Eye DiseasePurpose: To report the first case of a ...
-
Comparison of treatment cost and quality-of-life impact of thyroid eye disease therapiesPurpose : Teprotumumab was approved as...
-
Management of Endocrine Disease: Rituximab Therapy for Graves’ Orbitopathy – Lessons From Randomized Con...Rituximab (RTX) use in open-label series...
-
Teprotumumab Improves Short and Long-Term Clinical Outcomes in Thyroid Eye DiseaseMost adults with thyroid eye disease rec...
-
TEPEZZA (teprotumumab-trbw)- Frequently Asked Questions1. What is TEPEZZA? TEPEZZA is the firs...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.